<DOC>
	<DOCNO>NCT00865982</DOCNO>
	<brief_summary>In study , patient adenocarcinoma stomach , gastro-esophageal junction distal esophagus seem operable curative intent accord oncological surgical assessment treat 3 preoperative cycle DCX ( Docetaxel , Cisplatin , Capecitabine ) follow surgical resection , follow 3 postoperative cycle DCX .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Perioperative Chemotherapy With Docetaxel , Cisplatin Capecitabine ( DCX ) Patients With Gastro-esophageal Cancer</brief_title>
	<detailed_description>Perioperative chemotherapy show significantly improve R0 resection rate , disease free survival overall survival patient adenocarcinoma distal esophagus , gastro-esophageal junction stomach . Therefore perioperative chemotherapy new therapeutic standard ( Cunningham NEJM 2006 , MRC , Lancet 2002 , Boige ASCO 2007 ) . The best evaluated regime combination Epirubicin , Cisplatin 5-FU ( ECF ) ( Cunningham , NEJM 2007 ) . Cisplatin 5-FU seem important component form backbone regime ( Boige ASCO 2007 ) . Docetaxel new highly active agent gastric cancer . In randomized phase II study dual combination Docetaxel 5-FU seem show similar activity ECF , administer first line palliative treatment ( Thuss-Patience , JCO , 2005 ) . The three drug combination Docetaxel , Cisplatin , 5-FU significantly superior efficacy combination Cisplatin und 5-FU , superior quality life significantly superior overall survival ( Van Cutsem , JCO 2007 ) . It show Capecitabine oral prodrug 5-FU similarly active 5-FU replace intravenous 5-FU combination Cisplatin treatment gastric cancer . Capecitabine therefore FDA approve gastric cancer ( Cunningham , ASCO 2006 , Kang ASCO 2006 ) . It seem reasonable optimize perioperative chemotherapy include modern chemotherapeutics . The old standard ECF may improve integrate Docetaxel und Capecitabine . By add Docetaxel Cisplatin / flouropyrimidin backbone efficacy regime may improve . The replacement 5-FU Capecitabine may improve patients´ convenience possibly effectiveness combination . Therefore 3 drug combination Docetaxel , Cisplatin , Capecitabin ( DCX ) seem highly promising regime regard effectiveness convenience . In study patient adenocarcinoma stomach , gastro-esophageal junction distal esophagus seem operable curative intent accord oncological surgical assessment treat 3 preoperative cycle DCX follow surgical resection , follow 3 postoperative cycle DCX . The first application study medication within 21 day tumour assessment . There 3 preoperative cycle every 3 week . The experimental perioperative regime evaluate study Docetaxel/Cisplatin/Capecitabine DCX ( 75/ 60/ 1875 mg/m2 ) .The operation perform 3 6 week end third preoperative chemotherapy cycle ( count day 21 cycle 3 ) . Postoperative chemotherapy start within 6 - 12 week operation . 3 week end last chemotherapy final investigation ( end study visit ) do .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Signed dated consent Age minimum 18 maximum 75 year Primary diagnosis histologically proven adenocarcinoma stomach , gastroesophageal junction adenocarcinoma lower third esophagus Stage IIIII , TNMstaging : T34 , N03 , M0 T2 , N13 , M0 T1 , N2 , M0 . ( equivalent clinical staging uT34NXM0 , uT12N+M0 ) Intended curative resection accord evaluation experience surgeon Karnofskyperformanceindex &gt; 70 % Negative pregnancy blood test screen early 72 hour prior start chemotherapy woman child bear potential Adequate haematologic function liver renal function : neutrophil &gt; 1,5 x 109/L ; thrombocyte &gt; 100 x 109/L ; haemoglobin &gt; 10 g/dl , creatinine clearance &gt; 60 ml/min ( calculate accord Cockroft Gault ) , total bilirubin &lt; 1,0 x UNL ; AST ALT &lt; 1,5 x UNL , AP &lt; 2,5 x UNL Complete stag within 3 week prior start treatment ( CTscan thorax abdomen , endosonography , gastroscopy ) Ability keep appointment follow study protocol By CTscan , endoscopy endosonography measurable evaluable disease Former therapy gastroesophageal cancer ( operation , chemo radiotherapy ) Diagnosis another cancer last 5 year prior study entry cure operation ( exception insitucarcinoma cervix cure nonmelanomatose skin cancer ) Known dihydropyrimidinedehydrogenase ( DPD ) deficiency Known contraindication plan chemotherapeutics Presence distant metastases Anamnestic know serious disease concomitant diseases affect participation study , : Instable cardiac disease : symptomatic heart failure , symptomatic coronary artery disease , ventricular cardiac arrhythmia well control medication , myocardial infarction resuscitation within 6 month study Active infection necessitate systemic therapy uncontrolled infection Interstitial lung disease ( example : pneumonitis fibrosis lung ) indication interstitial lung disease chest xray CTscan respectively Active inflammatory bowel disease bowel diseases provoke chronic diarrhea ( define &gt; 4 bowel movement per day ) Neurological psychiatric disease include dementia , epilepsy untreated , symptomatic brain metastasis Limited hear ability Presence upper GI obstruction , lead inability swallow ground tablet Presence acute chronic systemic infection Presence bowel obstruction within last 30 day Pregnant lactate woman woman child bear potential men without adequate contraception ( high effective contraception , define Pearl Index &lt; 1 ) like birth control pill , hormone spiral , hormone implant , transdermal patch , combination two barrier method ( condom diaphragm ) , realize sterilization sexual abstinence study least 3 month last infusion Any situation may lead unacceptable high risk patient , participate study Parallel treatment another clinical study prior participation study Treatment therapy tumor parallel radiation Parallel treatment Sorivudine chemically relate substance like example Brivudin Symptomatic peripheral neuropathy NCICTCAE degree &gt; 2 Intolerance study medication galencic ingredient 5FU Detention psychiatric unit imprisonment ( AMG §40 Abs . 1 Nr . 4 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adenocarcinoma stomach , gastro-esophageal junction distal esophagus</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>gastro-esophageal junction</keyword>
	<keyword>docetaxel</keyword>
	<keyword>capecitabine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>perioperative chemotherapy</keyword>
</DOC>